AT1 receptors activation enhances the expression of MMP-2, MMP-13 and VEGF but not MMP-9 in B16F10 melanoma cells

Pakistan Journal of Biological Sciences

Volumn 14, Issue 17, 2011, Pages 821-830

  Akhavan, Maziar M ^a   Karimi, Mona ^a   Ghodrati, Maryam ^a   Falahtpishe, Hamidreza ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Angiotensin II; B16F10; Losartan; Melanoma; Tumor

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; COLLAGENASE 3; GELATINASE A; GELATINASE B; LOSARTAN; VASCULOTROPIN A;

ANIMAL; ARTICLE; DRUG EFFECT; HUMAN; MELANOMA; METABOLISM; MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; CELL LINE, TUMOR; HUMANS; LOSARTAN; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MELANOMA; MICE; RECEPTOR, ANGIOTENSIN, TYPE 1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 82255174066     PISSN: 10288880     EISSN: 18125735     Source Type: Journal    
DOI: 10.3923/pjbs.2011.821.830     Document Type: Article

References (40)

1. Ao, C., A. Li, A.A. Elzaawely and S. Tawata, 2008. MMP-13 Inhibitory activity of thirteen selected plant species from okinawa. Int. J. Pharmacol., 4: 202-207.
2. Brinkerhoff, C.E. and L.M. Matrisian, 2002. Matrix metalloproteinase: A tail of a frog that became a prince. Nat. Rev. Mol. Cell. Biol., 3: 207-214.
3. Egami, K., T. Murohara, T. Shimada, K.I. Sasaki and S. Shintani et al., 2003. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J. Clin. Invest., 112: 67-75.
4. El-Habashy, S.A., A.S. Khalifa, S.S. Abdel Hadi, N. AL Dahaba, M.A. Rasheed and T.R. Ilias, 2006. Significance of angiogenesis determination in pediatric solid tumors. J. Med. Sci., 6: 183-192.
5. El-Meghawry El-Kenawy, A., A.F. El-kott, M.M. Bin-Meferij and E.M. El-Gamal, 2006. Expressions of epidermal growth factor receptor, matrix metalloproteinase-2 and matrix metalloproteinase-9 in bladder carcinoma. J. Boil. Sci., 6: 911-915.
6. Eskens, F.A., 2004. Angiogenesis inhibitors in clinical development: Where are we now and where are we going?. Br. J. Cancer, 90: 1-7.
7. Feng, Y., H. Wan, J. Liu, R. Zhang and Q. Ma et al., 2010. The angiotensin-converting enzyme 2 in tumor growth and tumor-associated angiogenesis in non-small cell lung cancer. Oncol. Rep., 23: 941-948.
8. Fujita, M., I. Hayashi, S. Yamashina, M. Itoman and M. Majima, 2002. Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis and metastasis. Biochem. Biophys. Res. Commun., 294: 441-447.
9. Guruvayoorappan, C. and G. Kuttan, 2007. Antiangiogenic effect of rutin and its regulatory effect on the production of VEGF, IL-1β and TNF-α in tumor associated macrophages. J. Boil. Sci., 7: 1511-1519.
10. Herr, D., M. Rodewald, H.M. Fraser, G. Hack, R. Konrad, R. Kreienberg and C. Wolff, 2008. Potential role of renin-angiotensin system for tumor angiogenesis in receptor negative breast cancer. Gynecol. Oncol., 109: 418-425.
11. Hofmann, U.B., J.R. Westphal., G.N.P. Van Muijen and D.J. Ruiter, 2000. Matrix metalloproteinases in human melanoma. J. Invest. Dermatol., 115: 337-344.
12. Huang, W., L.F. Yu, J. Zhong, M.M. Qiao and F.X. Jiang et al., 2008. Angiotensin II type 1 receptor expression in human gastric cancer and induces MMP2 and MMP9 expression in MKN-28 cells. Digest. Dis. Sci., 53: 163-168.
13. Huang, X., C. Gottstein, R.A. Brekken and P.E. Thorpe, 1998. Expression of soluble VEGF receptor 2 and characterization of its binding by surface plasmon resonance. Biochem. Biophys. Res. Commun., 252: 643-648.
14. Ino, K., K. Shibata, H. Kajiyama, E. Yamamoto and T. Nagasaka et al., 2006. Angiotensins II type 1 receptor expression in ovarian cancer and its correlation with tumor angiogenesis and patient survival. Br. J. Cancer, 94: 552-560.
15. Jain, A. and S.C. Chaturvedi, 2008. Rationalization of physicochemical property of some substituted benzimidazole bearing acidic heterocyclic towards angiotensin ii antagonist: A QSAR approach. Asian J. Biochem., 3: 330-336.
16. Kang, Y.S., Y.G. Park, B.K. Kim, S.Y. Han and Y.H. Jee et al., 2006. Angiotensin II stimulates the synthesis of vascular endothelial growth factor through the p38 mitogen activated protein kinase pathway in cultured mouse podocytes. J. Mol. Endocrinol., 36: 377-388.
17. Kerbel, R. and J. Folkman, 2002. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer, 2: 727-739.
18. Kosaka, T., A. Miyajima, S. Shirotake, E. Kikuchi, M. Hasegawa, S. Mikami and M. Oya, 2010. Ets-1 and hypoxia inducible factor-1α inhibition by angiotensin II type-1 receptor blockade in hormone-refractory prostate cancer. Prostate, 70: 162-169.
19. Kuphal, S., R. Bauer and A.K. Bosserhoff, 2005. Integrin signaling in malignant melanoma. Cancer Metastasis Rev., 24: 195-222.
20. Lee, G.Y., W.W. Jung., C.S. Kang and I.S. Bang, 2006. Expression and characterization of human vascular endothelial growth factor (VEGF165) in insect cells. Protein. Expr. Purif., 46: 503-509.
21. Leung, D.W., G. Cachianes, W.J. Kuang, D.V. Goeddel and N. Ferrara, 1989. Vascular endothelial growth factor is a secreted angiogenic mitogen. Sciences, 246: 1306-1309.
22. Mahabeleshwar, G. H and T.V. Byzova, 2007. Angiogenesis in melanoma. Semin. Oncol., 34: 555-565.
23. Miyajima, A., T. Kosaka, T. Asano, K. Seta, T. Kawai and M. Hayakawa, 2002. Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibition tumor angiogenesis. Cancer Res., 62: 4176-4179.
24. Mocellin, S., 2006. Tumor vasculature: The achilles heel of cancer. Int. J. Cancer Res., 2: 176-187.
25. Otake, A.H., A. L Mattar, H.C. Freitas, C.M.L. Machado and S. Nonogaki et al., 2010. Inhibition of angiotensin II receptor 1 limits tumor-associated angiogenesis and attenuates growth murine melanoma. Cancer Chemother. Pharmacol., 66: 79-87.
26. Pasco, S., L. Ramont, F.X. Maquart and J.C. Monboisse, 2004. Control of melanoma progression by various matrikines from basement membrane macromolecules. Critical Rev. Oncol. Hematol., 49: 221-233.
27. Ramadan, M.M., H.A. Alazoony, M. Abo-Alyazied and S.H. Albebdary, 2007. Value of elective lymph node dissection in the management of malignant melanoma. J. Medical Sci., 7: 855-859.
28. Rmali, K.A., M.C.A. Puntis and W.G. Jiang, 2006. Level of the expression of VEGF-A, B, C, D and their receptors (FLT-1, KDR and FLT-4) and its correlation with prognosis in patients with colorectal cancer. Int. J. Cancer Res., 2: 31-41.
29. Sahib, H.B., N.A.H. Harchan, S.A.M. Atraqchi and A.A. Abbas, 2010. The role of medicinal herbs in angiogenesis related diseases. Int. J. Pharmacol., 6: 616-623.
30. Shi, R.Z., J.C. Wang, S.H. Huang, X.J. Wang and Q.P. Li, 2009. Angiotensin II induces vascular endothelial growth factor synthesis in mesenchymal stem cells. Exp. Cell. Res., 315: 10-15.
31. Shibuya, M., 1995. Role of VEGF-flt receptor system in normal and tumor angiogenesis. Adv. Cancer. Res., 67: 281-316.
32. Smith, L.M., A. Nesterova, S.C. Alley, M.Y. Torgov and P.J. Carter, 2006. Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97. Mol. Cancer Ther., 57: 1474-1482.
33. Steckelings, U.M., T. Wollschlager, J. Peters, B.M. Henz, B. Hermes and M. Artuc, 2004. Human skin: Source of and target organ for angiotensin II. Exp. Dermatol., 136: 148-154.
34. Tamarat, R., J.S. Silvestre, M. Durie and B.I. Levy, 2002. Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor and inflammation-related pathways. Lab. Invest., 82: 747-756.
35. Timar, J., L. Meszaros, A. Ladanyi, L.G. Puskas and E. Raso, 2006. Melanoma genomics reveals signatures of sensitivity to bio-and targeted therapies. Cell. Immunol., 244: 154-157.
36. Walter, T., A. Menrad, H.D. Orzechowski, G. Siemeiester, M. Paul and M. Schirner, 2003. Differential regulationof an in vivoangiogenesis by angiotensin II receptors. The FASEB. J., 170: 2061-2067.
37. Wang, L., S.R. Cai, C.H. Zhang, Y.L. He, W.H. Zhan, H. Wu and J.J. Peng, 2008. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type I receptor blockers on lymphangiogenesis of gastric cancerin a nude mouse model. Chinese Med. J., 121: 2167-2171.
38. Williams, R.N., S.L. Parsons, T.M. Morris, B.J. Rowlands and S.A. Watson, 2005. Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models. Eur. J. Surg. Oncol., 31: 1042-1050.
39. Zhang, D., M. Bar-Eli, S. Meloche and P. Brodt, 2004. Dual Regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor: The phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals. J. Biol. Chem., 279: 19683-19690.
40. Zigrino, P., I. Kohn, T. Bauerle, J. Zamek and J.W. Fox et al., 2009. Stromal expression of MMP-13 is required for melanoma invasion and metastasis. J. Invest. Dermatol., 129: 2686-2693.